Key Takeaways:
1. The Problem: Conventional R-alpha-lipoic acid (RALA) suffers from very low oral bioavailability due to chemical instability, making it difficult to reach effective blood concentrations.
2. The Solution: Converting it to a sodium salt (Sodium (R)-lipoate) fundamentally solves the stability issue.
3. The Evidence: Human studies show that Sodium (R)-alpha-lipoate achieves peak plasma concentrations (Cmax) over 20 times higher and a total bioavailability (AUC) more than 3 times greater than ordinary RALA.
The Conclusion: RALA sodium salt (NaRALA) is the key to translating alpha-lipoic acid's theoretical benefits into clinically accessible results.
However, its naturally bioactive form—R-alpha-lipoic acid (RALA)—is chemically unstable and prone to polymerization, leading to very poor absorption upon oral ingestion. This creates a significant gap: while numerous cell and animal studies confirm its benefits, the human body often cannot achieve effective blood levels through standard supplementation.
Converting the unstable free acid into its sodium salt form is a well-established pharmaceutical strategy to overcome this bottleneck. Na-R-ALA (i.e., Sodium (R)-alpha-lipoate) is the result of this approach.
1. The Science: Forming the R-(+)-ALA Sodium salt dramatically increases the compound's water solubility and chemical stability, preventing ineffective polymerization.
2. The Absorption Pathway: Upon ingestion, stabilized RALA quickly converts back to the free R-alpha-lipoic acid in the acidic environment of the stomach, gaining a critical advantage at the very start of absorption, leading to efficient uptake in the duodenum.
A pivotal 2007 human pharmacokinetic study provides direct comparative data. After administration of an equal dose (600 mg) of ordinary RALA versus Na-R-ALA:
1. Peak Plasma Concentration (Cmax): Levels with Na-R-ALA were 17 to 20 times higher than with ordinary RALA (e.g., increasing from 0.7 mcg/mL to 14.1 mcg/mL in a male subject).
2. Total Exposure (AUC): The total bioavailability (AUC) with Na-R-ALA was 2.6 to 3.3 times greater.
This confirms that the absorption efficiency of the RALA sodium salt is orders of magnitude higher than its unstabilized counterpart, marking the transition from "poorly absorbed" to "highly bioavailable."
Choosing stabilized RALA is a choice for science-based efficacy rooted in proven bioavailability.
Sinoway’s Advantages of R-Alpha Lipoic Acid Sodium:
1. Produced by advanced Enzyme technology, with much better function than ordinary ALA.
2. High quality: with assay of 99% up by HPLC
3. Competitive pricing in the global market
4. Large Capacity: 10ton/month with 500kg regular stock, ensuring reliable supply.
5. Regulatory Compliance: Facility passed US-FDA audit with US-FDA registeration No., Non-GMO certified
6. Stability Assurance: With 3 years stability data for RALA sodium, no need cool shipment.